Toxicology Resources > For Fellows-in-Training > Resources for FIT > ANTIDOTE Institute

The Antidote Institute:
Advancing New Toxicology Investigators in Drug Abuse and Original Translational Research Efforts

Sponsored by ACMT, The ToxInnovation Lab (UMASS), and The Chai Lab (Harvard Medical School)

Meet the 2022 Class

Medical toxicologists play an important role in defining the care of poisoned patients. Outside of providing clinical care, toxicologists have advanced the science around antidotal therapy, management of the poisoned patient, occupational exposures and substance use disorder. The discovery and development of the next practice driving advancements in toxicology require rigorous research, and a pipeline of new investigators to drive the field forward.  In order to support a career in research, toxicologists need knowledge and skills related to identifying and securing funding sources, scientific writing for knowledge dissemination, and ethical research conduct. Additionally, prospective investigators need to identify a strong network of mentors and collaborators to help them grow their own research program.  The ANTIDOTE Institute provides an opportunity for fellows and junior faculty to begin to develop their own area of investigation, network with peers and experienced investigators in the field, and gather practical knowledge on topics core to developing a successful research program. 

The Opportunity

One-year long course consisting of 1) focused, small group sessions with moderated peer review and mentorship with light didactics of core topics surrounding research fundamentals and 2) one-on-one mentorship from an established investigator in medical toxicology. This is not a formal didactic course on research methodology but rather an opportunity to establish and grow your research program with a network of external toxicology collaborators.


  • 1.5 - 2 hour online meeting, every other month, with 1-2 hours of pre-meeting homework (assigned at least 1 week prior). Active participation is expected; participants will be encouraged to submit their current work (study plans, grant proposals, abstracts, etc.) for review by the group, provide constructive feedback on other participant’s work, and bring their real world experiences to enhance the discussion. This is in addition to time spent on the participant's own research project, which will vary by individual.
  • Monthly one on one (virtual) meetings with assigned faculty mentor RE progress/questions between group meetings.


Applicants must be toxicology fellows or junior faculty (within 3 years of fellowship graduation) for the 2022-2023 academic year.  

Application Process

Interested applicants will need to provide:

  • A cover letter which includes a brief statement of interest and description of research interests/experience (1 page maximum)
    • Note: Research interests do not need to be well-developed at this stage; a basic description of interest is appropriate. The expectation is that the participants will be mentored during the initiative to develop their research ideas
  • CV
  • Letter of commitment from Med Tox program director confirming the applicant will have the availability and protected time to fully participate in all sessions (for fellow applicants only)

Please submit all application packets to ( by Feb 11, 2022.  Selected participants will be notified via email by Feb 25, 2022. The first virtual group meeting will be held in May 2022.

Questions about the program? For more information, please contact:

Stephanie Carreiro, MD

Program Chair


Stephanie Carreiro, MD, is an emergency medicine physician and medical toxicologist. She is a 2009 graduate of New York Medical College and completed her Emergency Medicine Residency in 2013 at Brown University. She completed a medical toxicology fellowship at the University of Massachusetts in 2015 and remained on faculty as an Assistant Professor of Emergency Medicine.  Dr. Carreiro has a passion for novel translational research, which she first discovered during residency while evaluating novel antidotes for cardiotoxicity in animal models.  She now focuses on clinical research in substance use disorder space, with a particular focus on the current opioid epidemic. Her current research interests include the utilization of novel technologies and serum biomarkers to evaluate drug toxicity, substance abuse, and addiction. Dr. Carreiro is also currently pursuing a PhD in Biomedical Sciences from the University of Massachusetts Medical School.

Peter R Chai, MD, MMS

Program Co-Chair


Dr. Peter R Chai is an assistant professor of emergency medicine and medical toxicology at Brigham and Women’s Hospital/Harvard Medical School, an affiliate research scholar at the Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology, and The Fenway Institute. He is also research faculty at the Dana Farber Cancer Institute. Dr. Chai’s career focuses on the development and implementation of technological solutions that detect and respond to changes in disease. His arc of translational science ranges from the design of novel robotic and sensor systems in animal models to human clinical trials to test the implementation of injectable and ingestible sensor systems and overlying behavioral science architecture to respond to disease states. Dr. Chai is principal investigator on grants from the National Institutes of Health, and other foundation and industry sources to develop a range of electronic devices ranging from ingestible electronic sensors that measure medication adherence, music that alters the experience of pain, robotic systems to understand population exposures to pharmaceuticals and infectious diseases and robotic systems to facilitate contactless care of patients in the emergency department.

Alison Meyn, MPH

Program Administrator


Alison is a Clinical Research Quality Analyst with ACMT. Alison received her MPH in Epidemiology from the School of Public Health at Georgia State University. She has been an epidemiologist for three years working in infectious disease and chronic disease with experience in case investigation, disease surveillance, database creation, data analytics, and more recently was a COVID-19 first responder. She has contributed to a number of public health projects in the fields of: Maternal and Child Health, Cancer, HIV, Oral Health, Smoking Cessation, and COVID-19.
Alison has worked in clinical research as well, working with private pharmaceuticals in Phase I and Phase II oncology clinical trials throughout the U.S. and Europe. Originally from Savannah, Georgia she now resides in Cape Coral, FL with her family and dogs.